Kamyar Shameli: Understanding the Coagulation Cascade – How Anticoagulants Prevent Blood Clots
Kamyar Shameli, Senior Scientist at Technical University of Munich, shared a post on LinkedIn:
“Understanding the Coagulation Cascade: How Anticoagulants Prevent Blood Clots
Description: The blood coagulation cascade is a precise, multi-step enzymatic process designed to prevent blood loss while keeping blood flowing safely through our vessels. At the center of this cascade is a critical turning point where multiple pathways converge: Factor Xa and Thrombin.
Here is how the coagulation cascade works and how anticoagulant therapies interrupt it:
The Conversion Mechanism
When coagulation is activated, Factor Xa converts Prothrombin into active Thrombin. Thrombin serves as the central key enzyme that drives the formation of Fibrin, creating a structural mesh that locks red blood cells and platelets into a stable clot.
How Anticoagulants Work: Anticoagulants interrupt this cascade by targeting key enzymes:
Direct Factor Xa Inhibitors amp; Direct Thrombin Inhibitors: Bind directly to Factor Xa or Thrombin to block their activity.
Heparin amp; Antithrombin Complex: Potentiate the bodys natural antithrombin mechanisms to neutralize Factor Xa and Thrombin.
Clinical Outcome
By reducing Factor Xa and Thrombin activity, fibrin formation drops significantly. This reduces the bodys ability to form and extend pathologically stable blood clots, helping prevent conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series